Auferstehung?

https://finance.yahoo.com/news/...host-conference-call-131500368.html  

Ziopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement
https://finance.yahoo.com/news/...announces-45-million-124047539.html

GlobeNewswire•July 29, 2019  

Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast

GlobeNewswireDecember 19, 2019

https://finance.yahoo.com/news/...entation-38th-annual-134510794.html

BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2020, at 9:30 a.m. PT (12:30 p.m. ET).  

Offering

• 27,8 Mio. neue Aktien zu je 3,25$ ~90 Mio. $
  
• Option auf weitere 4,2 Mio. Aktien
  

https://ir.ziopharm.com/news-releases/...ing-public-offering-common-0

 

Zahlen für 2019

• keine Umsätze
  
• Verlust 118 Mio. $
  
• Cash 80 Mio. $
  
• + ~90 Mio. $ auf dem Offering im Februar 2020
  
• MK 511 Mio. $
  

Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 

https://ir.ziopharm.com/news-releases/...l-results-fourth-quarter-and

 

MK 448 Mio. $  

Minderheitsinvestor WaterMill mischt Ziopharm auf

https://endpts.com/...inning-two-board-seats-and-removal-of-chairman/

 

Start Blutkrebsstudie

https://ir.ziopharm.com/news-releases/...arance-taiwans-first-ind-non

 

Jetzt Marktkapi ü1 Mrd.
--
https://seekingalpha.com/news/...y-after-naming-activist-to-the-board
 

 

Zahlen für Q2/21

• Cash 77 Mio. $
  
• MK 494 Mio. $
  

Closed venture debt financing with Silicon Valley Bank, strengthening balance sheet and extending cash runway into the fourth quarter of 2022

https://ir.ziopharm.com/news-releases/...arter-2021-corporate-updates

 

Die Quartalszahlen haben offensichtlich nicht den Markterwartungen entsprochen. MK 414 Mio. $  

Belegschaft wird um 50% reduziert

• ungefähr 60 Stellen sollen abgebaut werden
  
• die Cashreichweite soll dadurch bis H1/23 ausgedehnt werden
  
• MK 410 Mio. $
  

https://ir.ziopharm.com/news-releases/...egic-reduction-workforce-and

 

Probleme sein:

The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022

verschoben um mindestens ein halbes Jahr aufgrund von Problemen bei dem geplanten Lieferanten. Nun will man (trotz Stellenabbau ?) eine stabile Entwicklungsmannschaft UND eine eigene Fertigung aufbauen. Kein Wunder wenn man da sparen muss ( und damit allein wird es wohl kaum gehen).  

Kaufen u. liegen lassen....  

 

und sich umbenennen - aus ZIOP wird TCRT - ob es hilft?  

 

Könnte echt spannend werden....  

https://finance.yahoo.com/news/...-doses-first-patient-123000356.html
"Alaunos Therapeutics, Inc.
Mon, May 2, 2022, 2:30 PM·4 min read
TCRT
-7.28%
Alaunos Therapeutics, Inc.
First-in-human non-viral TCR-T cell therapy targeting shared hotspot mutations in solid cancers

First clinical product manufactured and administered to a patient using the Company’s in house cGMP manufacturing facility

Expect to report initial data in 2H22

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that the first patient has been dosed in its TCR-T Library Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications using the Company’s Sleeping Beauty transposon/transposase technology.

“Dosing the first patient in our TCR-T Library Phase 1/2 trial represents a significant accomplishment for Alaunos. Our team has worked diligently to achieve this milestone and bring our TCR-T cell therapy to cancer patients,” commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. “We believe that our adaptive trial design has the potential to allow us to rapidly and cost effectively identify the recommended phase 2 dose and quickly advance studies in the most promising indications. We look forward to an initial data readout in the second half of this year.”

The Phase 1/2 study is being conducted at The University of Texas MD Anderson Cancer Center and is an open label, dose escalation study, with patients being treated in one of three dose cohorts: 5x109, 4x1010, 1x1011 TCR-T cells. The trial is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers that have a matching human leukocyte antigen (HLA) and hotspot mutation pairing in Alaunos’ TCR-T library. The main study objectives are to define the maximum tolerated dose, recommended phase 2 dose and safety profile.

Carl June, M.D., Chairman of the Alaunos Scientific Advisory Board added, “This is a significant accomplishment as the first-in-human dosing of a patient with Sleeping Beauty TCR-T cells...."
 

 

Plus +35% und genau an der Linie angebufft..

 

Spannend...  

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
May 09, 2022 08:30 ET | Source: Alaunos Therapeutics, Inc.

...
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.

The conference call can be accessed by dialing 844-309-0618 (United States) or 661-378-9465 (International) with the conference code 2495623. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. After the live webcast, the event will be archived on the Company’s website for approximately 30 days after the call.

About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com  

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 10, 2022 08:30 ET | Source: Alaunos Therapeutics, Inc.

...
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development at Alaunos Therapeutics will present at the upcoming H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami Beach, FL.

Details for the presentations are below:

Event: H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022
Time: 5:00-5:30 pm ET
Location: Fontainebleau Miami Beach Hotel
Room: Splash 10

A live webcast of the presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com or by using the link here. A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.
       
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com